

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICATION OF: Chrai et al.

SERIAL NO: 09/095,616

GROUP ART UNIT: 3728

FILED: June 10, 1998

EXAMINER: Unassigned

FOR: Pharmaceutical Product and Method of Making

Attorney Docket No.: 176650-8

JC986 U.S. PTO
09/774346
01/31/01



Assistant Commissioner of Patents and Trademarks
Washington, DC 20231

SIR:

Pursuant to 37 C.F.R. §1.56(a), Applicant(s) hereby cite(s) the enclosed documents listed on the attached copy of Form PTO-1449 which are believed to be material to the patentability of the above-identified application.

This Information Disclosure Statement is filed in accordance with the paragraph of 37 CFR §1.97 indicated below:

§1.97(b) This Information Disclosure Statement is filed:

- (1) Within three months of the filing date of a national application; OR
- (2) Within three months of the date of entry of the national stage of an international application; OR
- (3) Before the mailing of a first Office Action on the merits.
No fee or statement is required.

§1.97(c) This Information Disclosure Statement is filed after the period specified in paragraph (b) above, but before the mailing date of either:

- (1) A Final Action or under 37 CFR §1.113; OR
- (2) A Notice of Allowance under 37 CFR §1.311; AND

is accompanied by either: (check one)

- The statement as specified in 37 CFR §1.97(e) set out below;
OR
 The fee of \$240.00 under 37 CFR §1.17(p).

Serial No:
Filed:

§1.97(d) This Information Disclosure Statement is filed after the mailing date of either:

- (1) a Final Action or under 37 CFR §1.113; OR
- (2) A Notice of Allowance under 37 CFR §1.311;

BUT filed on or before payment of the Issue Fee; AND
is accompanied by:

- (1) The statement as specified in 37 CFR §1.97(e) as set forth below; AND
- (2) Petition is hereby made under 37 CFR §1.97(d) for consideration of this Information Disclosure Statement; AND,
- (3) The petition fee of \$130.00 set out in 37 CFR §1.17(i).

§1.97(e) The undersigned Attorney hereby states that:

— each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing date of this Information Disclosure Statement;

or

— no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, or to the knowledge of the undersigned Attorney after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing date of the Information Disclosure Statement.

The Commissioner is authorized to charge payment of any fees associated with this communication or credit any overpayment to Deposit Account No. 03-0678.

FIRST CLASS CERTIFICATE	
I hereby certify that this correspondence is being deposited today with the U.S. Postal Service as First Class Mail in an envelope addressed to:	
Assistant Commissioner for Patents Washington, DC 20231	
William Squire, Esq.	Date <i>8/21/98</i>

Respectfully submitted,



William Squire, Esq.

Reg. No. 25,378
CARELLA, BYRNE BAIN, GILFILLAN,
CECCHI, STEWART & OLSTEIN
Six Becker Farm Road
Roseland, NJ 07068
Tel: (973)994-1700
Fax: (973)994-1744

Form PTO-1449

Atty. Docket:
176650-8Serial No.:
09/095,616INFORMATION DISCLOSURE STATEMENT

Applicant: Chrai et al.

Filing Date: June 10, 1998

Group: 3728

JCS86 U.S. PRO
09/17/98
01/31/01

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Sub-Class	Filing Date
	A1	4,307,555	12/29/81	Mlodzeniec et al.			10/4/79
	B1	4,029,758	6/14/77	Mlodzeniec et al.			12/15/75
	C1	4,069,084	1/17/78	Mlodzeniec et al.			4/4/77
	D1	4,128,445	12/5/78	Sturzenegger et al.			8/18/77
	E1	4,197,289	4/8/80	Sturzenegger et al.			8/15/78
	F1	5,207,217	5/4/93	Cocozza et al.			6/28/91
	G1	4,126,502	11/21/78	Dabal et al.			4/29/77
	H1	4,126,503	11/21/78	Gardner			4/29/77
	I1	4,128,444	12/5/78	Mlozenic			8/10/77
	J1	4,029,757	6/14/77	Mlodzeniec et al.			12/15/75
	K1	4,072,551	2/7/78	Dabal et al.			2/7/77
	L1	5,699,649	12/23/97	Abrams et al.			7/2/96
	M1						

FOREIGN PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Country	Class	Sub-Class	Translation
	N1						Yes No
	O1						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	P1	
	Q1	
	R1	
	S1	
	T1	

Examiner:

Date Considered:

EXAMINER:

Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

JC986 U.S. PRO
09/774346
01/31/01



APPLICATION OF: Chrai et al.

SERIAL NO: 09/095,616

GROUP ART UNIT: 1616

FILED: June 10, 1998

EXAMINER: Kathryne E. Shelborne

FOR: PHARMACEUTICAL PRODUCT AND METHOD OF MAKING

DOCKET NO: 176650-8

Assistant Commissioner for Patents
Washington, DC 20231

SIR:

Pursuant to 37 C.F.R. §1.56(a), Applicant(s) hereby cite(s) the enclosed documents listed on the attached copy of Form PTO-1449 which are believed to be material to the patentability of the above-identified application.

This Information Disclosure Statement is filed in accordance with the paragraph of 37 CFR §1.97 indicated below:

 §1.97(b) This Information Disclosure Statement is filed:

- (1) Within three months of the filing date of a national application; OR
- (2) Within three months of the date of entry of the national stage of an international application; OR
- (3) Before the mailing of a first Office Action on the merits.

No fee or certification is required.

X §1.97(c) This Information Disclosure Statement is filed after the period specified in paragraph (b) above, but before the mailing date of either:

- (1) A Final Action or under 37 CFR §1.113; OR
- (2) A Notice of Allowance under 37 CFR §1.311; AND

is accompanied by either: (check one)

 The Certification as specified in 37 CFR §1.97(e) set out below; OR

X The fee of \$230.00 under 37 CFR §1.17(p).

Serial No:
Filed:

§1.97(d) This Information Disclosure Statement is filed after the mailing date of either:

- (1) a Final Action or under 37 CFR §1.113; OR
- (2) A Notice of Allowance under 37 CFR §1.311;


BUT filed on or before payment of the Issue Fee; AND
is accompanied by:

- (1) The certification as specified in 37 CFR §1.97(e) as set forth below; AND
- (2) Petition is hereby made under 37 CFR §1.97(d) for consideration of this Information Disclosure Statement; AND,
- (3) The petition fee of \$130.00 set out in 37 CFR §1.17(i).


§1.97(e) The undersigned Attorney hereby certifies that:

- each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing date of this Information Disclosure Statement;
or
- no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, or to the knowledge of the undersigned Attorney after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing date of the Information Disclosure Statement.

The Commissioner is authorized to charge payment of any fees associated with this communication or credit any overpayment to Deposit Account No. 03-0678.

FIRST CLASS CERTIFICATE	
I hereby certify that this correspondence is being deposited today with the U.S. Postal Service as First Class Mail in an envelope addressed to:	
Assistant Comm. for Patents Washington, D.C. 20231	
	11/16/95
William Squire, Esq.	Date

Respectfully submitted,



William Squire, Esq.

Reg. No. 25,378

CARELLA, BYRNE, BAIN,
GILFILLAN, CECCHI, STEWART &
OLSTEIN

6 Becker Farm Road
Roseland, NJ 07068

Tel. No.: (973) 994-1700

Fax No. : (973) 994-1744

Attorney for Applicant(s)

Form PTO-1449

INFORMATION DISCLOSURE STATEMENT

Atty. Docket:

176650-8

Serial No.:

09/095,616

PTO

346

U.S.

77

01

31

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

01

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Sub-Class	Filing Date
	A1	US 4,128,445A	5/12/78	Sturzenegger et al.			
	B1	US 4,154,636	5/15/79	Motoyama et al.			
	C1						
	D1						
	E1						
	F1						
	G1						
	H1						
	I1						
	J1						
	K1						
	L1						
	M1						

FOREIGN PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Country	Class	Sub-Class	Translation
		EP 0065370 A	11/24/82	European			Yes
		WO98 20 861 A	5/22/98	International			Yes

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

Examiner:	Date Considered:
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.	

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

1C986 U.S. PRO
09/174346
01/31/01

APPLICATION OF: Chrai, et al.
SERIAL NO: 09/095,616
FILED: June 10, 1998
FOR: PHARMACEUTICAL PRODUCT AND METHOD OF MAKING
GROUP ART UNIT: 1616
EXAMINER: Kathryn E. Shelborne

Assistant Commissioner for Patents
Washington, DC 20231

SIR:

Pursuant to 37 C.F.R. §1.56(a), Applicant(s) hereby cite(s) the enclosed documents listed on the attached copy of Form PTO-1449 which are believed to be material to the patentability of the above-identified application.

This Information Disclosure Statement is filed in accordance with the paragraph of 37 CFR §1.97 indicated below:

§1.97(b) This Information Disclosure Statement is filed:

- (1) Within three months of the filing date of a national application; OR
- (2) Within three months of the date of entry of the national stage of an international application; OR
- (3) Before the mailing of a first Office Action on the merits.
No fee or statement is required.

§1.97(c) This Information Disclosure Statement is filed after the period specified in paragraph (b) above, but before the mailing date of either:

- (1) A Final Action or under 37 CFR §1.113; OR
- (2) A Notice of Allowance under 37 CFR §1.311; AND

is accompanied by either: (check one)

The statement as specified in 37 CFR §1.97(e) set out below;
OR

The fee of \$240.00 under 37 CFR §1.17(p).

§1.97(d) This Information Disclosure Statement is filed after the mailing date of either:

- (1) a Final Action or under 37 CFR §1.113; OR
- (2) A Notice of Allowance under 37 CFR §1.311;

BUT filed on or before payment of the Issue Fee; AND
is accompanied by:

- (1) The statement as specified in 37 CFR §1.97(e) as set forth below; AND
- (2) Petition is hereby made under 37 CFR §1.97(d) for consideration of this Information Disclosure Statement; AND,
- (3) The petition fee of \$130.00 set out in 37 CFR §1.17(i).

§1.97(e) The undersigned Attorney hereby states that:


- each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing date of this Information Disclosure Statement;
or
- no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, or to the knowledge of the undersigned Attorney after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing date of the Information Disclosure Statement.

The Commissioner is authorized to charge payment of any fees associated with this communication or credit any overpayment to Deposit Account No. 03-0678.

FIRST CLASS CERTIFICATE

I hereby certify that this correspondence is being deposited today with the U.S. Postal Service as First Class Mail in an envelope addressed to:


Assistant Commissioner for Patents
Washington, DC 20231


William Squire

March 23, 2000
Date

#60644 v1 - IDS-Trans-Delsys-8

Respectfully submitted,


William Squire

Reg. No. 25,378

Attorney for Applicant
CARELLA, BYRNE, BAIN, GILFILLAN,
CECCHI, STEWART & OLSTEIN

Six Becker Farm Road

Roseland, NJ 07068

Tel: (973) 994-1700

Fax: (973) 994-1744

Form PTO-1449

INFORMATION DISCLOSURE STATEMENTAtty. Docket:
176650-8Serial No.:
09/095,616

Applicant: Chrai, et al.

Filing Date: June 10, 1998

Group: 1616

1c985 U.S. PRO
09/17/1998 01/31/01

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Sub-Class	Filing Date
	A1						
	A2						
	A3						
	A4						
	A5						
	A6						
	A7						
	A8						
	A9						
	A10						
	A11						

FOREIGN PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Country	Class	Sub-Class	Translation
	B1	WO98/20861	May 22, 1998				<input type="checkbox"/> Yes <input type="checkbox"/> No
	B2	WO96/35413	November 14, 1996				<input type="checkbox"/> Yes <input type="checkbox"/> No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

C1	
C2	
C3	
C4	
C5	

Examiner:

Date Considered:

EXAMINER:

Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.